In Vivo Anti-Tumor Effect of PARP Inhibition in IDH1/2 Mutant MDS/AML Resistant to Targeted Inhibitors of Mutant IDH1/2

Treatment options for patients with relapsed/ refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are scarce. Recurring mutations, such as mutations in isocitrate dehydrogenase-1 and −2 (IDH1/2) are found in subsets of AML and MDS, are therapeutically targeted by mutant enzym...

Descripción completa

Detalles Bibliográficos
Autores principales: Gbyli, Rana, Song, Yuanbin, Liu, Wei, Gao, Yimeng, Biancon, Giulia, Chandhok, Namrata S, Wang, Xiaman, Fu, Xiaoying, Patel, Amisha, Sundaram, Ranjini, Tebaldi, Toma, Mamillapalli, Padmavathi, Zeidan, Amer M, Flavell, Richard A., Prebet, Thomas, Bindra, Ranjit S., Halene, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103411/
https://www.ncbi.nlm.nih.gov/pubmed/35273342
http://dx.doi.org/10.1038/s41375-022-01536-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103411/
https://www.ncbi.nlm.nih.gov/pubmed/35273342
http://dx.doi.org/10.1038/s41375-022-01536-x

Ejemplares similares